Travis Tagami, DO
Interventional Cardiology · Englewood, CONPI 1790190189
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,673 of the $25,361 with a category attached, or 65.7%. It is spread thinly across 39 manufacturers, the largest accounting for just 16.2%.
Across 422 payments — averaging $60.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Shockwave Medical, Inc$3K
- Inari Medical, Inc.$2K
- Stryker$2K
- Heartflow, Inc.$2K
- Abbott$2K
- plus $10K from 33 others
What the payments were for
- Consulting fees$2,0008%
- Travel & lodging$6,58026%
- Food & beverage$16,67366%
- Education$1080%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 99 | $4,103 |
| Shockwave Medical, Inc | 45 | $2,610 |
| Inari Medical, Inc. | 18 | $2,387 |
| Stryker | 5 | $2,175 |
| Heartflow, Inc. | 18 | $2,170 |
| Abbott | 20 | $2,135 |
| Abiomed | 43 | $2,078 |
| Bard Peripheral Vascular, Inc. | 9 | $1,343 |
| Edwards Lifesciences | 14 | $1,090 |
| Boston Scientific | 26 | $1,038 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $537 |
| Penumbra, Inc. | 6 | $486 |
| Asahi Intecc USA, Inc. | 8 | $456 |
| Novartis | 20 | $394 |
| Getinge USA Sales, LLC | 1 | $363 |
| E.r. Squibb & Sons, L.L.C. | 12 | $266 |
| Pfizer | 14 | $263 |
| Amgen | 14 | $236 |
| Novo Nordisk | 2 | $159 |
| Teleflex LLC | 1 | $150 |
| Bayer | 1 | $122 |
| AstraZeneca | 6 | $117 |
| Boehringer Ingelheim | 4 | $85 |
| Scpharmaceuticals Inc. | 4 | $83 |
| Merck | 3 | $66 |
| Esperion Therapeutics, Inc. | 3 | $55 |
| Cvrx, Inc. | 2 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $47 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $46 |
| Philips North America LLC | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Impulse Dynamics (USA) Inc. | 1 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Itamar Medical Inc | 1 | $24 |
| GSK | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Siemens Medical Solutions USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$4,128
- CT THROMBECTOMY SYSTEM KIT$4,128
- FFRct$1,866
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,380
- Impella$1,182
- Venclose Maven Catheter$1,102
- ONYX FRONTIER$1,047
- RESOLUTE ONYX$746
- OPTIS$540
- SAPIEN 3 Ultra RESILIA$509
- Indigo System$387
- Vasoview Hemopro 2$363
- SYMPLICITY G3$345
- MitraClip$342
- Omnilink Elite vascular stent system$341
- NAVITOR$269
- LifeVest$269
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$186
- PERIPHERAL VASCULAR$174
- GENERAL - THERAPIES$157
How this compares
$25,361 in reported general payments places this provider in the 75th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 165 | $202,919 |
| EntrestoSacubitril/Valsartan | 33 | $57,911 |
| JardianceEmpagliflozin | 41 | $56,538 |
| XareltoRivaroxaban | 41 | $50,808 |
| FarxigaDapagliflozin Propanediol | 27 | $31,836 |
| Repatha SureclickEvolocumab | 24 | $24,654 |
| VascepaIcosapent Ethyl | 19 | $12,644 |
| Ezetimibe | 149 | $3,665 |
| Rosuvastatin Calcium | 222 | $2,366 |
| Metoprolol Succinate | 210 | $2,340 |
| Prasugrel Hcl | 15 | $2,083 |
| Atorvastatin Calcium | 144 | $1,482 |
| Ranolazine ErRanolazine | 11 | $1,326 |
| Eplerenone | 19 | $1,028 |
| Amiodarone Hcl | 13 | $985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $263 | $202,919165 claims |
| NovartisEntresto | $394 | $57,91133 claims |
| Boehringer IngelheimJardiance | $85 | $56,53841 claims |
| Johnson & JohnsonXarelto | $20 | $50,80841 claims |
| AstraZenecaFarxiga | $117 | $31,83627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Englewood
- Ehrin ArmstrongEnglewood$718K
- Yonatan Bitton-FaiwiszewskiEnglewood$36K
- Regina LeeEnglewood$12K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.